Vyriad Revenue and Competitors

Location

$33.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vyriad's estimated annual revenue is currently $4.4M per year.(i)
  • Vyriad's estimated revenue per employee is $77,500
  • Vyriad's total funding is $33.9M.

Employee Data

  • Vyriad has 57 Employees.(i)
  • Vyriad grew their employee count by 54% last year.

Vyriad's People

NameTitleEmail/Phone
1
Chief StaffReveal Email/Phone
2
Associate Director Quality at VyriadReveal Email/Phone
3
Director Intellectual PropertyReveal Email/Phone
4
Director Process Development and MFG Science and TechnologyReveal Email/Phone
5
Co-founder, Chief Technical OfficerReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Director, Alliance ManagementReveal Email/Phone
8
Director LegalReveal Email/Phone
9
Sr Director Quality and ComplianceReveal Email/Phone
10
Chief Operating OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M509%N/AN/A
#2
$7.4M48-35%N/AN/A
#3
$0.9M620%N/AN/A
#4
$0.3M2-91%N/AN/A
#5
$3.6M235%N/AN/A
#6
$0.9M6-33%N/AN/A
#7
$5M323%N/AN/A
#8
$14.7M959%N/AN/A
#9
$14.7M950%$20.5MN/A
#10
$27.9M14413%$39.1MN/A
Add Company

What Is Vyriad?

At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. We believe our oncolytic viruses have tremendous potential to improve the lives of patients, inspire hope and change the way cancer is treated. Our goal is to develop effective viral-based therapies for patients, especially those with significant unmet needs. We are testing our oncolytic viruses as monotherapies or in combination with immuno-oncology drugs. Phase 1-2 clinical studies are under way in non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, bladder and other types of cancer. A Phase 2 trial in several additional forms of cancers is expected to begin enrolling patients by early 2020. Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, Merck KGaA/Pfizer and other leading research and medical institutions

keywords:N/A

$33.9M

Total Funding

57

Number of Employees

$4.4M

Revenue (est)

54%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vyriad News

2022-04-06 - Oral Vaccine Boosts COVID Immunity: study conducted on ...

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the...

2022-04-06 - Oral Vaccine Boosts COVID Immunity

About Vyriad, Inc. Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus...

2022-03-30 - Oral Vaccine Boosts COVID Immunity

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.9M574%N/A
#2
$5.1M5733%N/A
#3
$10.5M5719%N/A
#4
$13.9M57-2%N/A
#5
$16.8M570%N/A